{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:45:56Z","timestamp":1782229556223,"version":"3.54.5"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Aclaris Therapeutics, Inc."}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Lasers Surg Med"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>The objectives of this study were to evaluate the safety, tolerability, and efficacy of oxymetazoline hydrochloride cream, 1% (oxymetazoline) when used as an adjunctive treatment with energy\u2010based therapy for patients with moderate to severe facial erythema associated with rosacea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study Design\/Materials and Methods<\/jats:title><jats:p>In this Phase 4, multicenter, interventional, open\u2010label study, eligible patients received one of four energy\u2010based therapies (potassium titanyl phosphate laser, intense pulsed light therapy, pulsed\u2010dye laser Vbeam Perfecta, or pulsed\u2010dye laser Cynergy) on day 1 and day 29 and once\u2010daily application of oxymetazoline on days 3 through 27 and days 31 through 56. Improvement from baseline in Clinician Erythema Assessment (CEA) score, patient satisfaction measures, incidence of treatment\u2010emergent adverse events (TEAEs), and worsening from baseline on dermal tolerability assessments and the Clinician Telangiectasia Assessment (CTA) were assessed. Data were summarized using descriptive statistics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 46 patients (mean age, 51.1 years; 78.3% female) enrolled in this study. Similar numbers of patients received each of the energy\u2010based therapies in addition to oxymetazoline. All patients demonstrated an improvement from baseline in CEA during the study with 39 of 43 evaluable patients (90.7%) demonstrating an improvement 6\u2009hours posttreatment on day 56. Most patients were satisfied or very satisfied with treatment at the end of the study. All TEAEs were mild or moderate in severity. Some patients experienced worsening in dermal tolerability assessment symptoms (range: 4\u201321 patients; 8.7\u201345.7%). Worsening in CEA and CTA were each reported by three patients (6.5%) at any time during the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Treatment with oxymetazoline as adjunctive therapy with energy\u2010based therapy was safe, well tolerated, and reduced facial erythema in patients with moderate to severe persistent facial erythema associated with rosacea. Lasers Surg. Med. \u00a9 2020 The Authors. <jats:italic>Lasers in Surgery and Medicine<\/jats:italic> published by Wiley Periodicals LLC<\/jats:p><\/jats:sec>","DOI":"10.1002\/lsm.23253","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T05:26:41Z","timestamp":1588829201000},"page":"55-65","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Oxymetazoline and Energy\u2010Based Therapy in Patients with Rosacea: Evaluation of the Safety and Tolerability in an Open\u2010Label, Interventional Study"],"prefix":"10.1002","volume":"53","author":[{"given":"Emil A.","family":"Tanghetti","sequence":"first","affiliation":[{"name":"Center for Dermatology and Laser Surgery 5601 J Street Sacramento California 95819"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Skin Laser &amp; Surgery Specialists of New York and New Jersey 115 E 57th Street, #400 New York New York 10022"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Dover","sequence":"additional","affiliation":[{"name":"Skin Care Physicians 1244 Boylston Street (Route 9) Chestnut Hill Massachusetts 02467"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy G.","family":"Geronemus","sequence":"additional","affiliation":[{"name":"Laser &amp; Skin Surgery Center of New York 317 East 34th Street New York New York 10016"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zane","family":"Bai","sequence":"additional","affiliation":[{"name":"Allergan Giralda Farms, Dodge Drive Madison New Jersey 07940"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Alvandi","sequence":"additional","affiliation":[{"name":"Allergan Giralda Farms, Dodge Drive Madison New Jersey 07940"},{"name":"Avanir Pharmaceuticals, Inc. 30 Enterprise, Suite 200 Aliso Viejo California 92656"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart D.","family":"Shanler","sequence":"additional","affiliation":[{"name":"Aclaris Therapeutics, Inc. 640 Lee Road, Suite 200 Wayne Pennsylvania 19087"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16481"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15122"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.027"},{"issue":"2","key":"e_1_2_7_5_1","first-page":"47","article-title":"Quality of life in individuals with erythematotelangiectatic and papulopustular rosacea: Findings from a web\u2010based survey","volume":"11","author":"Zeichner JA","year":"2018","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_7_6_1","unstructured":"HarperJ BaldwinHE BaradaranS PatelV. A comparative analysis of dermatology life quality index in rosacea and other common dermatological conditions [poster]. Presented at: Annual Meeting of the Winter Clinical Dermatology Conference Hawaii; January 12\u201017 2018; Lahaina HI."},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.06.009"},{"issue":"3","key":"e_1_2_7_8_1","first-page":"26","article-title":"Advances in understanding and managing rosacea: Part 2: The central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea","volume":"5","author":"Del Rosso JQ","year":"2012","journal-title":"J Clin Aesthet Dermatol"},{"issue":"2","key":"e_1_2_7_9_1","first-page":"71","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: A status report on physical modalities and devices","volume":"93","author":"Tanghetti E","year":"2014","journal-title":"Cutis"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/14764172.2017.1279334"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.11.1369"},{"key":"e_1_2_7_12_1","unstructured":"Rhofade [package insert]. Charleston SC: EPI Health;2019."},{"issue":"1","key":"e_1_2_7_13_1","first-page":"97","article-title":"Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: Findings from the first REVEAL trial","volume":"17","author":"Kircik LH","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"e_1_2_7_14_1","first-page":"611","article-title":"Pivotal trial of the efficacy and safety of oxymetazoline cream 1.0% for the treatment of persistent facial erythema associated with rosacea: Findings from the second REVEAL trial","volume":"17","author":"Baumann L","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.044"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6262"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23176"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.23186"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocd.12952"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22953"},{"issue":"6","key":"e_1_2_7_21_1","first-page":"621","article-title":"Clinically relevant reduction in persistent facial erythema of rosacea on the first day of treatment with oxymetazoline cream 1.0%","volume":"17","author":"Tanghetti EA","year":"2018","journal-title":"J Drugs Dermatol"},{"issue":"11","key":"e_1_2_7_22_1","first-page":"1201","article-title":"Topical oxymetazoline cream 1.0% for persistent facial erythema associated with rosacea: Pooled analysis of the two phase 3, 29\u2010day, randomized, controlled REVEAL trials","volume":"17","author":"Stein\u2010Gold L","year":"2018","journal-title":"J Drugs Dermatol"}],"container-title":["Lasers in Surgery and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Flsm.23253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lsm.23253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/lsm.23253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/lsm.23253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T20:47:27Z","timestamp":1693687647000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/lsm.23253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1002\/lsm.23253"],"URL":"https:\/\/doi.org\/10.1002\/lsm.23253","archive":["Portico"],"relation":{},"ISSN":["0196-8092","1096-9101"],"issn-type":[{"value":"0196-8092","type":"print"},{"value":"1096-9101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"2019-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}